DOI: https://doi.org/10.22141/2224-0713.2.72.2015.78400

Efficacy of Combined Neurometabolic Therapy in Patients with Primary and Recurrent Cerebral Hemispheric Ischemic Stroke

A.A. Koziolkin, L.V. Novikova

Abstract


To study the efficacy of combined neuroprotective therapy with Ceraxon® and Actovegin in acute period of primary and recurrent cerebral hemispheric ischemic stroke we have carried out complex clinical neurological and neuropsychological examination of 186 patients aged from 45 to 85 years. Combined neuroprotective, neurometabolic, angioprotective, antioxidant, neurotrophic effects of Ceraxon® and Aktovegin promoted greater regression of neurological and cognitive deficits, improved clinical and social outcome of the acute period of the disease. The combined use of these drugs has proven its superiority over mononeuroprotective therapy.


Keywords


ischemic stroke; acute period; neurometabolic therapy

References


Особенности эпидемиологии инвалидности при заболеваниях нервной системы в Украине / Хобзей Н.К., Мищенко Т.С., Голик В.А. // Международный неврологический журнал. — 2011. — № 5(43). — C. 15-19.

Инсульт. Реалии и потребности оказания нейрохирургической помощи в Украине / Сапон Н.А., Гук А.П., Никифорова А.Н. [и др.] // Український нейрохірургічний журнал. — 2013. — № 4. — C. 43-47.

Епідеміологія цереброваскулярних захворювань в Україні / Зозуля І.С., Зозуля А.І. // Український медичний часопис. — 2012. — № 5 (85). — C. 38-41.

Characteristics of Cognitive Impairment in Patients with Post-stroke Aphasia / Lee B., Pyun S.B. // Ann. Rehabil. Med. — 2014. — № 38(6). — Р. 759-65.

Neuroprotective properties of citicoline: facts, doubts and unresolved issues / Grieb P. // CNS Drugs. — 2014. — № 3. — Р. 185-193.

Citicoline: pharmacological and clinical review / Secades J.J. // Rev. Neurol. — 2011. — № 52. — Р. S1-S62.

The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke / Álvarez-Sabín J., Román G.C. // Brain Sci. — 2013. — № 3. — Р. 1395-1414.

Citicoline, use in cognitive decline: Vascular and degenerative / García-Cobos R., Frank-Garcia A. [et al.] // J. Neurol. Sci. — 2010. — № 299. — Р. 188-192.

Citicoline in pre-clinical animal models of stroke: A meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial / Bustamante A., Giralt D. [et al.] // J. Neurochem. — 2012. — № 123. — Р. 217-225.

Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design / Guekht A., Skoog I., Korczyn A.D., Zakharov V., Eeg M., Vigonius U.A. // J. Dement. Geriatr. Cogn. Dis. Extra. — 2013. — № 14. — Р. 459-467.

Actovegin: a biological drug for more than 5 decades / Buchmayer F., Pleiner J., Elmlinger M.W. et al. // Wien Med. Wochenschr. — 2011. — № 161. — Р. 80-88.

Neuroprotection in vascular dementia: a future path / Skoog I., Korczyn A.D., Guekht A. // J. Neurol. Sci. — 2012. — № 322. — Р. 232-236.

Neuroprotective and Anti-Oxidative Effects of the Hemodialysate Actovegin on Primary Rat Neurons in Vitro / Elmlinger M.W., Kriebel M., Ziegler D. // Neuromolecular Med. — 2011. — № 13(4). — Р. 266-274.




Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта